ADMA's ASCENIV Margins Outrun a Shrinking BIVIGAM
The Q3 beat is real, but the McKesson/secondary-immunodeficiency bridge is arriving slower than advertised and DSOs are stretching.
ADMA · Earnings Call · 2026-11-04
A margin beat dressed as a revenue beat
ADMA Biologics' third quarter looked clean on the surface: revenue of $141.1 million, ASCENIV revenue of $124.7 million up 31% year over year and 21% sequentially, BIVIGAM of $15.4 million versus $23.8 million a year ago, gross margin of 71% versus 56%, adjusted EBITDA of $77.3 million up 32%, and GAAP net income of $49.9 million up 37%. The company raised its minimum adjusted EBITDA guidance to at least $275 million from $265 million and adjusted net income to at least $180 million from $170 million while keeping revenue guidance at 'at least $530 million.' That combination is the tell: this was a margin-and-mix raise, not a top-line raise. Total revenue has compounded from $3 million in 2016 to $124 million by Q2 2026, and the Q3 print pushed it to $141.1 million. The operating leverage is no longer theoretical. The demand language is unusually concrete for this company. Patient demand is now described as durable and recurring, with patients staying on ASCENIV for a year or longer and prescribers at a record level exiting Q3. Adam Grossman said the company is seeing increases in both prescribers and new patient starts, and the ASCENIV franchise is doing the heavy lifting while BIVIGAM shrinks.What changed: BIVIGAM is still shrinking, but the defense is more scientific
The old ADMA story was a niche immunoglobulin maker fighting a standard-IG price war. The new one is a high-margin ASCENIV story using scientific evidence to defend a declining BIVIGAM franchise. Management has not changed its pricing posture: “We continue to prioritize sustainable commercial participation rather than matching aggressive competitor rebating and discounting.” — Adam S. Grossman, Founder, Director, President · 2026-11-04 That is consistent with the May call, when Grossman said plainly: “I never wanted to be in the standard IG business.” — Adam Grossman, President and Chief Executive Officer · 2026-05-07 The difference now is that ADMA is trying to turn peer-reviewed thrombosis-related data and real-world outcomes into a competitive moat rather than simply waiting for the discounting cycle to end. That is where scientific differentiation and deep discounting collide. BIVIGAM revenue fell 35% year over year and 21% sequentially, and management only claims signs of stabilization in underlying utilization. The company is presenting real-world data from 127 medically complex primary immunodeficiency patients at ACAAI and has published research on thrombosis-related product attributes. The hope is that payers and clinicians will evaluate BIVIGAM on more than price. But the tape is unlikely to reward that argument until BIVIGAM revenue actually inflects.McKesson: the growth bridge that has not fully arrived
The most important tension in this report is the secondary-immunodeficiency story. For several quarters, management framed McKesson as the distribution key to the secondary immune deficiency market, which sits outside ADMA's legacy call points. In August, Grossman said: “McKesson is an important part of our go-forward strategy to continue penetrating with ASCENIV.” — Adam Grossman, President and Chief Executive Officer · 2026-08-05 He added that the GPO buying groups associated with McKesson were primarily focused on secondary immune deficiency. On this call, the emphasis shifted. Primary immune deficiency is leading the growth, while secondary immune deficiency is described as slower than expected. Grossman said:That is not a collapse of the thesis, but it is a delay. The McKesson channel was supposed to broaden the addressable base; instead, the near-term growth is still coming from the same refractory PI population ADMA has been penetrating for years. The company says it is above its previous 4% penetration estimate within a 25,000-patient target market, which implies more room, but the secondary-IDN opportunity remains mostly unproven. The DSO issue is related. ADMA reported DSOs of 110 days, above its 90-to-105-day target, driven by distributor order timing. In August, CFO Terry Kohler said McKesson would be an important factor in pushing DSOs back into range. On this call, she was more cautious: “It may take a little bit longer than previously expected.” — Terry Kohler, Chief Financial Officer and Treasurer · 2026-11-04 That is a small operational crack, but it matters because the bull case depends on cash conversion matching the earnings story. Receivables to revenue stood at 111% in the latest fundamentals snapshot, and the market will want that ratio to fall as ASCENIV scales.Primary immune deficiency continues to lead the charge with growth... the secondary immune deficient population... is slower than what we would have hoped or anticipated, but the opportunity still exists and it still remains.